Specialty Pharmacy News

The FDA indicated in a letter to SPAARx that future compounding legislation will omit the term “specialty pharmacy.”

A bill passed by the Florida legislature would allow pharmacists to substitute biosimilars for brand-named biologics provided that a number of criteria are met.

The value of a specialty therapy lies not only in its clinical safety and efficacy, but also in how its price compares with other therapies in its class, found a new report.

United States spending on specialty prescription drugs is projected to increase 67% by the end of 2015, according to a forecast released today by Express Scripts.

The National Association of Specialty Pharmacy (NASP) announced it will host its 2013 Fall Strategic Business Exchange meeting on October 14-16, 2013 in San Antonio.

Specialty drugs drove spend in 2012 and accounted for almost two-thirds of spending on branded products.

The FDA approved the first companion diagnostic to detect epidermal growth factor receptor (EGFR) gene mutations, which are present in approximately 10% of non-small cell lung cancers.

David Hileman, senior vice president of Omnicare, recently discussed how market access to oncology medications is changing and presented strategies manufacturers can use to support patient need through compliant distribution channels.

The Specialty Pharmacy Association of America (SPAARx), the largest national association representing the broad interests of the specialty pharmacy industry, celebrated its official launch at the 2013 Annual Armada Specialty Pharmacy Summit in Las Vegas, NV, on May 8, 2013

Representatives from the pharmaceutical industry and the managed care arena recently squared off at the 2013 Armada Specialty Pharmacy Summit about the costs and benefits of copay offset programs for biologics.